Sean F. Brady

Sean F. Brady

Auto-generated profile, based on publicly available information

Sean F. Brady

Laboratory of Genetically Encoded Small Molecules, The Rockefeller University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Nature
Verified
Journal Article
Open access
PDF file
LCLouis J. Cohen
Louis J. Cohen
DEDaria Esterhazy
Daria Esterhazy
SKSeong-Hwan Kim
Seong-Hwan Kim
CLChristophe Lemetre
Christophe Lemetre
RARhiannon Rose Aguilar
Rhiannon Rose Aguilar
SBSean F. Brady
Sean F. Brady
Commensal bacteria are believed to have important roles in human health. The mechanisms by which they affect mammalian physiology remain poorly understood, but bacterial metabolites are likely to be key components of host interactions. Here we use bioinformatics and synthetic biology to mine the human microbiota for N-acyl amides that interact with G-protein-coupled receptors (GPCRs). We found that N-acyl amide synthase genes are enriched in gastrointestinal bacteria and the lipids that they encode interact with GPCRs that regulate gastrointestinal tract physiology. Mouse and cell-based models demonstrate that commensal GPR119 agonists regulate metabolic hormones and glucose homeostasis as efficiently as human ligands, although future studies are needed to define their potential physiological role in humans. Our results suggest that chemical mimicry of eukaryotic signalling molecules may be common among commensal bacteria and that manipulation of microbiota genes encoding metabolites that elicit host cellular responses represents a possible small-molecule therapeutic modality (microbiome-biosynthetic gene therapy).

12 February 2018 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
BHBradley M. Hover
Bradley M. Hover
SKSeong-Hwan Kim
Seong-Hwan Kim
MKMicah Katz
Micah Katz
ZCZachary Charlop-Powers
Zachary Charlop-Powers
JOJeremy G. Owen
Jeremy G. Owen
SBSean F. Brady
Sean F. Brady
Despite the wide availability of antibiotics, infectious diseases remain a leading cause of death worldwide 1 . In the absence of new therapies, mortality rates due to untreatable infections are predicted to rise more than tenfold by 2050. Natural products (NPs) made by cultured bacteria have been a major source of clinically useful antibiotics. In spite of decades of productivity, the use of bacteria in the search for new antibiotics was largely abandoned due to high rediscovery rates2,3. As only a fraction of bacterial diversity is regularly cultivated in the laboratory and just a fraction of the chemistries encoded by cultured bacteria are detected in fermentation experiments, most bacterial NPs remain hidden in the global microbiome. In an effort to access these hidden NPs, we have developed a culture-independent NP discovery platform that involves sequencing, bioinformatic analysis and heterologous expression of biosynthetic gene clusters captured on DNA extracted from environmental samples. Here, we describe the application of this platform to the discovery of the malacidins, a distinctive class of antibiotics that are commonly encoded in soil microbiomes but have never been reported in culture-based NP discovery efforts. The malacidins are active against multidrug-resistant pathogens, sterilize methicillin-resistant Staphylococcus aureus skin infections in an animal wound model and did not select for resistance under our laboratory conditions.

5 January 2022 in Nature
Verified
Journal Article
Closed access
PDF file
ZWZongqiang Wang
Zongqiang Wang
BKBimal Koirala
Bimal Koirala
YHYozen Hernandez
Yozen Hernandez
MZMatthew Zimmerman
Matthew Zimmerman
SPSteven Park
Steven Park
SBSean F. Brady
Sean F. Brady

17 October 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
JCJohn Chu
John Chu
XVXavier Vila-Farres
Xavier Vila-Farres
DIDaigo Inoyama
Daigo Inoyama
MTMelinda Ternei
Melinda Ternei
LCLouis J Cohen
Louis J Cohen
SBSean F Brady
Sean F Brady
The synthetic bioinformatic natural products (syn-BNPs) approach identifies putative natural products that are validated directly by independent synthesis. Its application led to the identification of humimycins, non-ribosomal peptides that have antimicrobial activity in mice. Here we present a natural product discovery approach, whereby structures are bioinformatically predicted from primary sequence and produced by chemical synthesis (synthetic-bioinformatic natural products, syn-BNPs), circumventing the need for bacterial culture and gene expression. When we applied the approach to nonribosomal peptide synthetase gene clusters from human-associated bacteria, we identified the humimycins. These antibiotics inhibit lipid II flippase and potentiate β-lactam activity against methicillin-resistant Staphylococcus aureus in mice, potentially providing a new treatment regimen.


17 August 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LCLouis J. Cohen
Louis J. Cohen
HKHahk-Soo Kang
Hahk-Soo Kang
JCJohn Chu
John Chu
YHYun-Han Huang
Yun-Han Huang
EGEmma A. Gordon
Emma A. Gordon
SBSean F. Brady
Sean F. Brady
Significance: In this study, we demonstrate a method for rapidly identifying bacterial effector genes and gene products from human commensal bacteria. Identification of specific effector genes and small molecules improves our understanding of how bacteria might interact with human cells and contribute to both health and disease. The small molecules we isolated, N -acyl-3-hydroxyglycines, resemble endogenously produced N -acyl-amide signaling molecules and were found to activate the human G-protein–coupled receptor (GPCR) GPR132/G2A. G2A has potentially important implications for autoimmune disease and atherosclerosis. Finding commensal small molecules that appear to structurally mimic host signaling metabolites provides greater insight into how commensal bacteria may interact with human physiology and the methods required for future discovery of other commensal effectors.